Merck & Co., Inc.

Report azionario NYSE:MRK

Capitalizzazione di mercato: US$302.3b

Merck Crescita futura

Criteri Future verificati 4/6

Merck prevede che gli utili e i ricavi cresceranno rispettivamente di 21.2% e 3.6% all'anno. Si prevede che l'EPS crescerà di 21.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 40.7% in 3 anni.

Informazioni chiave

21.2%

Tasso di crescita degli utili

21.89%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili14.5%
Tasso di crescita dei ricavi3.6%
Rendimento futuro del capitale proprio40.66%
Copertura analitica

Good

Ultimo aggiornamento22 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Nov 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...

Recent updates

Aggiornamento della narrazione • May 21

Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026

Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.
Aggiornamento della narrazione • May 19

Merck Completes Acquisition of Terns Pharmaceuticals

Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.
Aggiornamento della narrazione • May 17

MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance

Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.
Seeking Alpha • May 16

A Futuristic Synthesis Indeed

Summary A recent paper by Merck details the industrial synthesis of enlicitide, which is a beast of a macrocyclic peptide. Just looking at the structure tells you that this must be a ferociously active molecule with huge commercial potential, because there is just no way that anyone is going to make this on scale - or find a way to make this on scale! - otherwise. Several companies have tried over the years to come up with a small-molecule approach that could lead to an orally dosed therapy as opposed to an injectable, and Merck has apparently made it over the finish line with this one. Read the full article on Seeking Alpha
Articolo di analisi • May 11

Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...
Aggiornamento della narrazione • May 02

MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple

Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.
Aggiornamento della narrazione • Apr 19

Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)

Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.
Aggiornamento della narrazione • Apr 18

MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple

Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
Aggiornamento della narrazione • Apr 04

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.
Aggiornamento della narrazione • Mar 21

MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple

The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.
Aggiornamento della narrazione • Mar 06

MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside

Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.
Aggiornamento della narrazione • Feb 20

MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance

Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.
Aggiornamento della narrazione • Feb 06

MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple

Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
Nuova narrazione • Jan 30

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.
Aggiornamento della narrazione • Jan 23

MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance

Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.
Aggiornamento della narrazione • Jan 09

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.
Aggiornamento della narrazione • Dec 24

MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations

Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.
Aggiornamento della narrazione • Dec 14

Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs

based on Q3 result
Aggiornamento della narrazione • Dec 10

MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance

Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.
Articolo di analisi • Dec 02

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...
Aggiornamento della narrazione • Nov 26

MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead

Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.
Articolo di analisi • Nov 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...

Previsioni di crescita degli utili e dei ricavi

NYSE:MRK - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202875,73423,37825,08627,2825
12/31/202770,30520,42522,82723,3927
12/31/202666,8485,55611,71518,2467
3/31/202665,7688,93514,11517,890N/A
12/31/202565,01118,25412,36016,472N/A
9/30/202564,23519,03413,04917,065N/A
6/30/202563,61616,40614,72218,534N/A
3/31/202563,92217,43417,03920,878N/A
12/31/202464,16817,11718,09621,468N/A
9/30/202463,17412,14814,84018,264N/A
6/30/202462,48013,73613,14716,690N/A
3/31/202461,4032,30611,04014,757N/A
12/31/202360,1153659,14313,006N/A
9/30/202359,3154,60813,16717,190N/A
6/30/202358,3113,11110,82815,075N/A
3/31/202357,86913,03011,26215,673N/A
12/31/202259,28314,51914,70719,095N/A
9/30/202258,97415,32215,24919,696N/A
6/30/202257,16916,64114,39818,891N/A
3/31/202253,97813,91012,87017,220N/A
12/31/202148,70412,3459,66114,109N/A
9/30/202146,1315,9088,40113,072N/A
6/30/202143,9063,6656,95311,897N/A
3/31/202141,8574,7936,65911,184N/A
12/31/202041,5184,5195,81210,241N/A
9/30/202042,4389,4926,90611,041N/A
6/30/202043,9069,0707,99611,645N/A
3/31/202046,3129,3998,94712,811N/A
12/31/201939,1215,690N/A13,440N/A
9/30/201945,9709,314N/A12,238N/A
6/30/201944,3679,362N/A10,805N/A
3/31/201943,0738,399N/A11,103N/A
12/31/201842,2946,220N/A10,922N/A
9/30/201841,7293,347N/A11,349N/A
6/30/201841,2591,341N/A7,385N/A
3/31/201840,7251,579N/A7,320N/A
12/31/201740,1222,394N/A6,451N/A
9/30/201739,8042,845N/A6,064N/A
6/30/201740,0165,086N/A10,206N/A
3/31/201739,9294,346N/A8,489N/A
12/31/201639,8073,920N/A10,376N/A
9/30/201639,9075,492N/A10,990N/A
6/30/201639,4445,133N/A11,330N/A
3/31/201639,3854,614N/A12,427N/A
12/31/201539,4984,442N/A12,538N/A
9/30/201539,76510,781N/A7,128N/A
6/30/201540,2499,850N/A8,165N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MRK ( 21.2% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di MRK ( 21.2% all'anno) cresceranno più rapidamente del mercato US ( 16.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MRK cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di MRK ( 3.6% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MRK ( 3.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MRK sarà molto alto tra 3 anni ( 40.7 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/25 18:00
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Merck & Co., Inc. è coperta da 48 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Charles ButlerBarclays
Emily FieldBarclays